-
BMRN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
BioMarin Pharmaceutical (BMRN)
Company Profile
Quarter (USD) | Sep 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 675.45 mm | 675.45 mm | 675.45 mm | 675.45 mm | 675.45 mm | 675.45 mm |
Cash burn (monthly) | 23.85 mm | 1.58 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 66.75 mm | 4.42 mm | n/a | n/a | n/a | n/a |
Cash remaining | 608.70 mm | 671.03 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 25.5 | 425.3 | n/a | n/a | n/a | n/a |
13F holders | Current |
---|---|
Total holders | 549 |
Opened positions | 131 |
Closed positions | 73 |
Increased positions | 171 |
Reduced positions | 168 |
13F shares | Current |
---|---|
Total value | 14.54 tn |
Total shares | 183.91 mm |
Total puts | 1.19 mm |
Total calls | 1.63 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 22.74 mm | $1.87 tn |
Vanguard | 18.99 mm | $1.56 tn |
Primecap Management | 18.79 mm | $1.55 tn |
Dodge & Cox | 13.93 mm | $1.15 tn |
Capital Research Global Investors | 9.69 mm | $798.01 bn |
STT State Street | 9.64 mm | $793.33 bn |
Viking Global Investors | 7.06 mm | $581.54 bn |
AMP Ameriprise Financial | 4.70 mm | $387.06 bn |
Avoro Capital Advisors | 4.56 mm | $375.21 bn |
Norges Bank | 3.62 mm | $297.99 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Nov 24 | Alexander Hardy | Common Stock | Payment of exercise | Dispose F | No | No | 66.03 | 14,295 | 943.90 k | 134,156 |
12 Nov 24 | Charles Greg Guyer | Common Stock | Sell | Dispose S | No | No | 66.3743 | 5,278 | 350.32 k | 68,909 |
31 Oct 24 | Alexander Hardy | Common Stock | Grant | Acquire A | No | No | 56.007 | 300 | 16.80 k | 148,451 |
31 Oct 24 | Charles Greg Guyer | Common Stock | Grant | Acquire A | No | No | 56.007 | 55 | 3.08 k | 74,187 |
30 Sep 24 | Gregory R Friberg | Common Stock | Grant | Acquire A | No | No | 0 | 7,870 | 0.00 | 29,060 |
30 Sep 24 | Gregory R Friberg | Common Stock | Grant | Acquire A | No | No | 0 | 21,190 | 0.00 | 21,190 |
30 Sep 24 | Gregory R Friberg | Stock Option (Right to Buy Common Stock) Common Stock | Grant | Acquire A | No | No | 70.29 | 49,850 | 3.50 mm | 49,850 |
13 Sep 24 | Henry J Fuchs | Common Stock | Payment of exercise | Dispose F | No | No | 84.9 | 12,098 | 1.03 mm | 185,074 |
30 Apr 24 | Henry J Fuchs | Common Stock | Grant | Acquire A | No | No | 68.646 | 300 | 20.59 k | 197,172 |